These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16729460)

  • 21. [Champix has become a registered drug].
    Blázovics A
    Orv Hetil; 2007 Jan; 148(4):190. PubMed ID: 17344137
    [No Abstract]   [Full Text] [Related]  

  • 22. Personal imports of drugs to Japan in 2005--an analysis of import certificates.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2008 Oct; 33(5):545-52. PubMed ID: 18834370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating nanomedicine.
    Nat Mater; 2007 Apr; 6(4):249. PubMed ID: 17401411
    [No Abstract]   [Full Text] [Related]  

  • 24. [New EU law--an improvement for Norwegian children?].
    Kalikstad B
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1770-2. PubMed ID: 19756062
    [No Abstract]   [Full Text] [Related]  

  • 25. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 26. [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs].
    Johannesson M; Berglund EG
    Lakartidningen; 2007 Jul 11-24; 104(28-29):2099. PubMed ID: 17702388
    [No Abstract]   [Full Text] [Related]  

  • 27. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European Union revamps toxicology testing in attempt to limit animal use, improve prediction.
    Sinha G
    J Natl Cancer Inst; 2006 Jun; 98(11):728-9. PubMed ID: 16757693
    [No Abstract]   [Full Text] [Related]  

  • 30. Performing trials in children with rheumatic diseases: comment on the editorial by Lehman.
    Ruperto N; Martini A; Lovell DJ; Giannini EH; ;
    Arthritis Rheum; 2008 Apr; 58(4):1201-2; author reply 1203. PubMed ID: 18383366
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine].
    Nolte H; Harving H; Backer V
    Ugeskr Laeger; 2007 Dec; 169(50):4366-7. PubMed ID: 18211797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy.
    Inoue Y; Toiyama Y; Tanaka K; Miki C; Kusunoki M
    Jpn J Clin Oncol; 2009 Jun; 39(6):367-75. PubMed ID: 19395468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.
    Malinowski HJ; Westelinck A; Sato J; Ong T
    J Clin Pharmacol; 2008 Aug; 48(8):900-8. PubMed ID: 18524997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European norms for disinfection testing.
    Fraise AP
    J Hosp Infect; 2008 Oct; 70 Suppl 1():8-10. PubMed ID: 18994675
    [No Abstract]   [Full Text] [Related]  

  • 35. Monoclonal antibodies: clinical and regulatory issues.
    Thorpe R
    Trends Biotechnol; 1993 Feb; 11(2):40-2. PubMed ID: 7765291
    [No Abstract]   [Full Text] [Related]  

  • 36. A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005.
    Oelrich B; Peters R; Jung K
    Eur Urol; 2007 Oct; 52(4):1238-48. PubMed ID: 17673361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newer monoclonal antibodies for hematological malignancies.
    Castillo J; Winer E; Quesenberry P
    Exp Hematol; 2008 Jul; 36(7):755-68. PubMed ID: 18565392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tysabri's troubles return.
    Hoag H
    Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
    [No Abstract]   [Full Text] [Related]  

  • 39. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Omalizumab (Xolair). Product description].
    Laursen LC
    Ugeskr Laeger; 2007 Mar; 169(11):993-5. PubMed ID: 17371630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.